Group 1 - OTC Markets Group Inc. announced that Bora Pharmaceuticals Co., Ltd. has been added to the OTCQX® Best Market eligible trading list, allowing its shares to trade under the ticker "BORAY" [1] - The inclusion in the OTCQX market enables Bora Pharmaceuticals to efficiently expand its financing channels in the U.S. capital market while maintaining its primary listing in Taiwan [1] - OTCQX requires companies to meet high financial standards and adhere to best corporate governance practices, ensuring compliance with applicable securities laws [1] Group 2 - Jason Paltrowitz, Executive Vice President of OTC Markets Group, expressed that Bora Pharmaceuticals is the first Taiwanese issuer to join the OTCQX market, enhancing its visibility among U.S. investors and showcasing OTCQX's global influence [2] - Bobby Sheng, Chairman of Bora Group, highlighted that this milestone allows for cross-market trading in the U.S. through the Level 1 ADR program, which broadens investment channels for U.S. investors while maintaining liquidity for shareholders [3] - Bora Pharmaceuticals aims to become a truly global enterprise, with over 95% of its revenue coming from markets outside Taiwan, and emphasizes the importance of liquidity, trust, and long-term value creation [3] Group 3 - Bora Pharmaceuticals, established in 2007, is a leading pharmaceutical services company focused on integrating contract research, development, and manufacturing (CDMO) with commercial expertise to accelerate product development and meet global patient needs [4] - The company is actively expanding its R&D and sales infrastructure, focusing on niche and rare disease markets to improve patient quality of life [4] - Bora is committed to innovation and sustainable growth through investments in talent, infrastructure, and biopharmaceutical business expansion, setting new standards in the pharmaceutical and CDMO industries [4]